Clarie (Clarithromycin) is a prescription medicine used in situations involving certain distressing symptoms caused by susceptible bacterial infections in several key areas of the body. The medication is applied to conditions where the underlying bacterial proliferation is the source of the distressing symptoms, which supports the patient during difficult episodes by easing distress related to the symptomatic illness.

As an antibiotic, Clarithromycin is used to treat bacterial infections across multiple domains.

It is commonly used for conditions characterized by periods of heightened symptoms such as community-acquired pneumonia, acute exacerbations of bronchitis, acute otitis media, and certain skin structure infections. Furthermore, Clarie may assist with symptomatic management for patients with peptic ulcers where the infection contributes to recurrent abdominal pain and burning.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed.”

It helps address symptom clusters that may become intense or disruptive, like persistent cough, chest congestion, localized pain, and fever. Clarie contributes to easing the overall symptom load, assisting with maintaining functional stability during symptomatic phases.

---

Quick Fact: Relief for Respiratory Distress Clarie is considered relevant in managing severe symptomatic presentations of lower respiratory infections, applied in addressing symptom clusters that include persistent cough and chest congestion.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Clarie — official regulatory information

The official eligibility profile for Clarie (Clarithromycin) is defined by patient age, pre-existing health conditions, and specific co-administered medicines, as stated in government-approved labeling.

---

Populations for Whom Use is Contraindicated

Absolute prohibition applies to patients with:

• Known hypersensitivity to Clarithromycin or any macrolide antibacterial drug.
• A history of cholestatic jaundice or hepatic dysfunction associated with prior use of the medicine.
• Known QT prolongation, ventricular arrhythmia, or uncorrected electrolyte disturbances (e.g., hypokalemia).
• Severe hepatic failure combined with renal impairment.
• Concomitant use with specific drugs, including Lovastatin, Simvastatin, Colchicine (in renal/hepatic impairment), Ergot Alkaloids, Pimozide, and Lurasidone.

---

Age-Related Eligibility and Condition-Specific Rules

Classification	Population Entity	Regulatory Status
Approved	Adults and Adolescents (12 years)	Eligible for standard use.
Restricted	Pediatric Population (6 months to 12 years)	Use is permitted, but the oral suspension formulation must be used.
Not Established	Infants (< 6 months)	Safety and efficacy have not been established.
Conditional Use	Severe Renal Impairment ( CrCl < 30 mL/min)	Use requires mandatory dose reduction (one-half).

---

Pregnancy and Lactation Eligibility

Official labeling advises that use during pregnancy is not recommended without carefully weighing the benefits against the risks due to documented embryofetal toxicity in animal studies. Clarithromycin is excreted into breast milk; therefore, nursing might have to be discontinued.

Clarie (Clarithromycin) is officially documented as a strong inhibitor of the Cytochrome P450 3A (CYP3A) enzyme system. This pharmacokinetic interaction reduces the clearance of numerous co-administered medicines, resulting in an increase in their systemic exposure.

---

Contraindicated Combinations

Co-administration with the following substances is strictly prohibited by regulatory authorities due to the documented risk of serious adverse events:

• Pimozide and Cisapride: Prohibited due to the risk of QT prolongation and severe cardiac arrhythmias.
• Lovastatin and Simvastatin: Prohibited due to the documented potential for significantly increased plasma levels, which raises the risk of myopathy and rhabdomyolysis.
• Ergot Alkaloids (Ergotamine, Dihydroergotamine): Prohibited due to the documented risk of acute ergot toxicity.
• Lurasidone and Lomitapide: Prohibited as Clarithromycin may significantly increase their systemic exposure.

---

Interaction-Related Restrictions and Conditions

Classification	Detail	Condition/Requirement
Food Interaction	Mandatory timing rule for one formulation.	Extended-Release Tablets must be taken with food.
Population-Specific Restriction	Contraindication for Colchicine.	Applies only to patients with concurrent renal or hepatic impairment.
Other Noted Interactions	Increased exposure is documented for drugs like Warfarin, Digoxin, and Immunosuppressants (e.g., Tacrolimus).	Requires specific monitoring according to regulatory standards.

Clarie (Clarithromycin) functions by exerting a specific mechanism of action that interrupts the fundamental protein synthesis pathway of susceptible bacteria. Its action is focused exclusively on the internal machinery of the prokaryotic cell, resulting in the arrest of bacterial growth.

---

Targeted Inhibition of Bacterial Protein Synthesis

This mechanism involves the drug's access to the bacterial cytoplasm to directly block the cell's ability to create essential structural and functional proteins. Clarithromycin acts as a reversible, high-affinity inhibitor by binding to the 50S ribosomal subunit . This interaction physically obstructs the exit pathway for new protein chains, stopping the crucial process of polypeptide chain elongation.

---

Arrest of Bacterial Growth and Replication

The resulting cascade from ribosomal binding is the arrest of bacterial growth (bacteriostasis). By preventing the synthesis of essential components, the drug effectively stops the bacteria from multiplying. This physiological consequence is the basis of its action: it restricts the proliferation of the bacterial population, creating the necessary conditions to facilitate the clearance of remaining microorganisms by the host's intrinsic immune system.

Clarie (Clarithromycin) is officially administered via the oral route as immediate-release tablets, extended-release (XR) tablets, or an oral suspension. It is also available as a powder for solution for infusion, typically reserved for short-term intravenous (IV) use in hospitalized patients.

The standard immediate-release tablet is generally dosed at 250 mg to 500 mg per unit and is taken twice daily (every 12 hours). This formulation may be consumed with or without food. In contrast, the Extended-Release tablet is usually administered as a 1000 mg total dose, taken once daily (every 24 hours). A key administration requirement for the XR form is that it must be swallowed whole and taken with food to maintain the correct release of the active substance; it must not be crushed, broken, or chewed.

The liquid oral suspension formulation is used for pediatric patients where dosing is calculated based on body weight, typically 15 mg/ kg/ day divided into two daily doses. The total course of therapy is usually set for 7 to 14 days, based on the infection being addressed. For adult patients with severe renal impairment (creatinine clearance less than 30 mL/ min), the official protocol requires the total daily dose to be reduced by 50%. If a dose is missed, instructions advise taking it as soon as remembered, but if it is almost time for the next scheduled dose, the missed dose should be skipped to prevent doubling the intake.

Research Evidence / Overview of Studies for Clarie

This section provides an overview of the types of clinical and pharmacological studies conducted for Clarie (Clarithromycin), outlining the research landscape without offering clinical interpretation or treatment advice. Findings describe group patterns and observed changes in studies but should not be used for individual predictions.

---

Evidence for Use in Acute Respiratory Infections (Pneumonia and Bronchitis)

Clinical investigations and pharmacological studies have monitored the use of Clarie within treatment frameworks for lower and upper respiratory conditions, such as community-acquired pneumonia and acute exacerbations of bronchitis. These studies evaluated outcomes related to microbial status and the measured change in symptom presentation.

Research examined endpoints focused on the status of the underlying infection and the change in associated symptom clusters, such as cough, fever, and chest congestion. Studies reported how symptoms evolved in the observed populations, contributing to the understanding of short-term symptom changes in conditions involving acute or disruptive episodes.

---

Research in Special Populations and Specific Formulations

Clinical trials and observational data were evaluated in various patient groups. For conditions like acute otitis media, the paediatric population has been a key group studied for this medicine, especially with the availability of the liquid suspension formulation.

Research examined the effects in older adults and has also explored the use of Clarie in individuals with comorbidities, such as heart conditions. Findings describe patterns observed in the studies across these different age and health status groups. The results apply only to the populations studied, and the research does not determine whether an individual will respond similarly.

---

Long-Term Research and Evidence Duration

Research has explored outcomes that extend beyond the typical short course of antibiotic treatment. A key study monitored outcomes in a specific patient group, including those with coronary artery disease, for a period of years following a two-week course of the medicine.

Findings from this specific long-term trial indicate an unexpected pattern of increased all-cause and cardiovascular-related risk in that specific population. This was a finding observed in some studies that was reported as potentially related to the medicine, while findings were mixed in others. This evidence contributed to the development of updated regulatory cautions for use in this specific patient group.

Key Studies & References

1. Clarithromycin: NIH StatPearls
2. Clarithromycin (Systemic): NIH MedlinePlus overview (common uses)

Common questions about Clarie (FAQ)

Q: What is the intended use of Clarie according to official documentation?

According to regulatory documents, Clarie is officially used to treat several types of bacterial infections. These indications include infections of the respiratory tract, such as sinusitis and certain types of pneumonia. It is also used as part of combination therapy to treat stomach ulcers caused by the H. pylori bacteria.

Q: Can Clarie be taken with or without food?

Whether Clarie is taken with or without food depends on the formulation described by the official label. Official instructions indicate that the immediate-release (IR) tablet can be taken regardless of food. Conversely, official information states that the extended-release (XR) tablet is to be taken with food to ensure the medicine works as described.

Q: Does the efficacy of Clarie vary by individual patient factors?

Official documents indicate that the required dosage may vary based on certain patient factors. For instance, patients with severe kidney impairment may require a dose reduction to address how the body processes the medicine. Warnings also note that the drug can affect individuals with pre-existing liver concerns differently.

Q: Is there a specific time of day Clarie is usually recommended to be taken?

Official product information specifies the frequency, but not a mandatory time of day. The drug is prescribed to be taken either once or twice daily. The official instruction is to adhere to the recommended time interval consistently, but a specific morning or evening time is usually not required.

Q: How quickly does Clarie typically start to take effect?

Official information indicates that the medicine reaches its peak level in the blood within a few hours of administration. However, patients are often advised that it may take a few days to notice a significant improvement in symptoms. Official instructions stress the importance of completing the full course as prescribed to ensure the infection is fully treated.

Q: Can Clarie be taken at the same time as common over-the-counter pain relievers?

Clarie has the potential to interact with a high number of other medicines, including some common over-the-counter pain relievers. Because of this risk, official guidance emphasizes the necessity of providing your healthcare provider with a complete list of all medications you are taking. This list includes all prescribed, non-prescribed, and herbal products, as described in patient safety leaflets.

Q: Are there any known interactions between Clarie and herbal supplements?

Official warnings indicate that some herbal supplements can interact with Clarie. For example, the herbal product St. John's Wort may interfere with how your body processes the medicine. Official safety guidance recommends informing your prescribing doctor of any supplements being taken.

Q: What are the most commonly reported side effects of Clarie?

Official product labeling identifies several commonly reported side effects. These typically include gastrointestinal issues such as stomach pain, diarrhea, nausea, and vomiting. Many patients also report a temporary change in taste or an unpleasant metallic taste in the mouth.

Q: Does Clarie have any official warnings related to driving or operating machinery?

Yes, official warnings mention that the medicine may affect a patient's alertness and awareness. Clarie has been noted to cause potential side effects such as dizziness, confusion, or disorientation. For this reason, patients are advised that they should confirm how the drug affects them before engaging in activities like driving a car or operating heavy machinery.

Q: Is Clarie appropriate for use in older adults?

Clarie can be used in older adults, but regulatory warnings suggest special caution is required. Official documents note that this population may be more likely to experience heart rhythm side effects (arrhythmias). This risk profile is a consideration noted in the regulatory documentation.

Q: Is there any research evidence supporting the use of Clarie in adolescents?

Yes, official product information confirms that Clarie is approved for use in adolescents. For certain infections, it is indicated for use in those older than 12 years at the standard adult dosage. The regulatory approval for this age group is based on clinical evidence provided to the regulatory authority.

Q: What conditions make someone ineligible to use Clarie?

Official documents indicate that these reasons include a known allergy to Clarie or any drug in the macrolide class. It is also contraindicated if there is a prior history of jaundice or severe liver problems associated with its use, or co-administration with certain prohibited medicines.

Q: Is it true that Clarie can affect mood or sleep patterns?

Official safety documents note that the drug can potentially affect sleep and mental status. Difficulty sleeping, known as insomnia, is listed as a potential side effect. Other central nervous system effects, such as dizziness or confusion, have also been reported with its use.

Q: Are there any specific food or beverage items that should be avoided while using Clarie?

General advice in official patient information is to maintain your normal diet while taking Clarie. The most critical food-related instruction is ensuring the extended-release tablet is taken with food for proper absorption. Beyond the requirement for the extended-release tablet, official documents do not list specific food items that are generally restricted.

Q: What is the official safety classification of Clarie?

Official documents classify Clarie's use in pregnancy based on existing evidence. In the United States, it is categorized as Pregnancy Category C. This classification describes the condition under which the drug's use may be considered during pregnancy, based on a risk-benefit assessment.

Q: Is Clarie associated with any long-term health concerns?

Yes, regulatory warnings exist regarding potential long-term safety concerns for a specific population. For patients with coronary artery disease, official documentation notes a possible low increased risk of death (all-cause) that may persist for up to 10 years following treatment. This specific warning is noted in regulatory documentation.

Q: Does Clarie require any special storage conditions?

The different formulations of Clarie have specific storage requirements. Tablets are generally stored at room temperature and should be protected from light and moisture. The liquid oral suspension is instructed not to be refrigerated and is typically discarded after 14 days.

Q: What kind of monitoring or lab tests might be needed while using Clarie?

For some patients, a healthcare professional may recommend monitoring with blood tests. This monitoring may include checking liver function and kidney function before or during treatment. This monitoring is typically noted as relevant when a patient has pre-existing conditions.

Q: Are the side effects of Clarie generally reversible?

The majority of common side effects, such as temporary digestive issues, are expected to stop once the full course is completed. Rare, severe adverse events like liver failure are noted to be usually reversible with timely intervention. However, patients are directed to be aware of the signs of serious reactions.

Q: Is Clarie ever used in combination with other treatments for the same condition?

Yes, Clarie is frequently used as one component of a combination therapy for certain infections. A primary example is its use in multi-drug regimens for the eradication of H. pylori (a common cause of stomach ulcers). It is also used in combination with other drugs to treat Mycobacterium avium complex (MAC) infections.

Q: Does Clarie affect birth control methods?

Official guidance indicates that Clarie does not directly interfere with the effectiveness of hormonal birth control. However, if a patient experiences severe side effects like uncontrolled vomiting or severe diarrhea, this can prevent oral contraceptives from being properly absorbed. Patients are encouraged to discuss this possibility with a healthcare professional.

Q: Are there reports of Clarie interacting with alcohol use?

Official sources do not generally list alcohol consumption as a direct contraindication when taking Clarie. However, official sources advise patients to discuss their alcohol use with their healthcare provider. This is because alcohol can sometimes affect the overall response to medication.

Q: What does the term 'contraindicated' mean in relation to Clarie?

In regulatory terms, a 'contraindication' is a specific situation where the medicine should not be used because it could cause serious harm. For Clarie, this includes things like having a known allergy or taking certain other prohibited medicines. This information ensures the drug is only used when the benefits outweigh the severe risks.

Q: Why do some patients stop taking Clarie?

Regulatory warnings note that patients are to discontinue the medicine immediately if serious adverse effects occur. These severe reactions include a severe skin rash or signs of a serious allergic reaction. Patients are also advised to seek help if they experience signs of liver damage or persistent, watery diarrhea.

Q: What is the evidence regarding Clarie's use in patients with liver concerns?

Official warnings address the medicine's use in patients with pre-existing liver conditions. Clarie has the potential to cause or worsen liver damage (hepatotoxicity). It is contraindicated in patients with severe liver and/or kidney impairment who are also receiving certain other medicines.

Q: What is the half-life of Clarie?

Official pharmacokinetics data provides specific information on how long the medicine stays in the body. The elimination half-life is the time it takes for half of the dose to be removed. This is typically between 3 to 4 hours for lower doses and can extend to 5 to 7 hours for higher doses.

Q: Are generic versions of Clarie available?

Yes, Clarie is available as a generic medicine in many regions. The generic name for the drug is Clarithromycin. Regulatory bodies confirm that generic versions contain the same active ingredient and meet the same quality standards as the brand-name product.

Q: Can Clarie be stopped suddenly, or does it require a gradual reduction?

As an antibiotic, official instructions direct patients to complete the entire prescribed course without interruption. The medicine is generally stopped at the conclusion of the prescribed course rather than requiring a gradual reduction (tapering). Stopping too early can lead to incomplete treatment of the infection.

Q: Are there common misunderstandings about what Clarie is used for?

Yes, official patient information often clarifies a common misunderstanding about antibiotics. Clarie is specifically designed to treat infections caused by bacteria and is ineffective against common viral infections like the cold or flu. It is intended for use only when a bacterial infection is suspected or confirmed.

How to Store and Dispose of Clarie (Clarithromycin)

Storage Conditions

Clarie Tablets and Extended-Release Tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). All forms must be kept in the original container, tightly closed, and protected from light, moisture, and excessive heat. The medicine must not be frozen and should be stored out of the sight and reach of children.

Suspension Stability Rules

Once the Oral Suspension is mixed, it must not be refrigerated and any remaining liquid must be discarded after 14 days of reconstitution, as required by stability guidelines.

Disposal Instructions

Unused or expired Clarie should be disposed of through an authorized drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (like coffee grounds) and sealed before placing in household trash. Do not flush or dispose of the product in wastewater.